Effectiveness of Very Low Doses of Immunotherapy in Advanced Renal Cell Cancer
Author Information
Author(s): C Buziol, G De Palma, R Passalacqua, D Potenzoni, F Ferrozzi, MA Cattabiani, L Manentil, A Borghetti
Primary Institution: Universita degli Studi di Parma
Hypothesis
Can very low doses of immunotherapy effectively control metastatic renal cell cancer with acceptable toxicity?
Conclusion
The study found that very low doses of immunotherapy resulted in a 20% overall response rate and a 44-month survival rate of 44% in patients with metastatic renal cell cancer.
Supporting Evidence
- One patient achieved a complete response after treatment, lasting over 55 months.
- Three patients showed partial responses, with one maintaining it for 37 months.
- The estimated actuarial 44-month survival rate was 44%.
Takeaway
Doctors tested a new treatment for kidney cancer using very small doses of medicine, and it helped some patients live longer without too many side effects.
Methodology
Twenty-one patients with metastatic renal cell cancer were treated with recombinant interleukin 2 and interferon alpha in a phase II study, with treatment cycles repeated at 4-month intervals.
Potential Biases
Selection bias may have influenced the survival data due to the non-randomized nature of the study.
Limitations
The study was non-randomized and had a small sample size, which may limit the generalizability of the results.
Participant Demographics
Patients were nephrectomized, with a median age of 64 years, including 5 females and 16 males.
Statistical Information
Confidence Interval
95% confidence interval 6-44%
Want to read the original?
Access the complete publication on the publisher's website